Drugs / Adebelimumab
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06332300 | Feb 2024 → Feb 2025 | non-small cell lung carcinoma | Jiangsu Province Nanjing Brain Hospital | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06188650 | Dec 2023 → Sep 2025 overdue | non-small cell lung carcinoma | Ningbo Medical Center Lihuili Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adebelimumab | “After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab.” NCT06188650 ↗ |